Conformational analysis of the NMDA receptor antagonist (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) designed by a novel conformational restriction method based on the structural feature of cyclopropane ring

Chemical and Pharmaceutical Bulletin

Volumn 50, Issue 7, 2002, Pages 966-968

  Ono, Sizuka ^a   Ogawa, Kiyoshi ^b   Yamashita, Kanako ^b   Yamamoto, Tamotsu ^b   Kazuta, Yuji ^a   Matsuda, Akira ^a   Shuto, Satoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b ASAHI CHEMICAL INDUSTRY CO   (Japan)

Author keywords

Calculation; Conformational restriction; Cyclopropane; NMDA receptor; NMR

Indexed keywords

1 PHENYL 2 (1 AMINOPROPYL) N,N DIETHYLCYCLOPROPANECARBOXAMIDE; CYCLOPROPANE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; 1-PHENYL-2-(1-AMINOPROPYL)-N,N-DIETHYLCYCLOPROPANECARBOXAMIDE; AMINO ACID RECEPTOR BLOCKING AGENT; MILNACIPRAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ARTICLE; CALCULATION; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG DESIGN; DRUG DETERMINATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; NUCLEAR OVERHAUSER EFFECT; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING; X RAY CRYSTALLOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

CRYSTALLOGRAPHY, X-RAY; CYCLOPROPANES; DRUG DESIGN; EXCITATORY AMINO ACID ANTAGONISTS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036637184     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.50.966     Document Type: Article

References (37)

1. Silverman R. B., "The Organic Chemistry of Drug Design and Drug Action," Academic Press, San Diego, 1992.
2. Kozikowski A. (ed.), "Drug Design for Neuroscience," Raven Press, New York, 1993.
3. Wermuth C. G. (ed.), "The Practice of Medicinal Chemistry," Academic Press, San Diego, 1996.
4. For example see: Shimamoto K., Ofune Y., J. Med. Chem., 39, 407-423 (1996).
5. For example see: Armstrong D. P., Cannon J. G., J. Med. Chem., 13, 1037-1039 (1970).
6. For example see: Stammer S. H., Tetrahedron, 46, 2231-2254 (1990).
7. For example see: Martin S. F., Dwyer M. P., Hartmann B., Knight K. S., J. Org. Chem., 65, 1305-1318 (2000).
8. For example see: Sekiyama T., Hatsuya S., Tanaka Y., Uchiyama M., Ono N., Iwayama S., Oikawa M., Suzuki K., Okunishi M., Tsuji T., J. Med. Chem., 41, 1284-1298 (1998).
9. Shuto S., Ono S., Hase Y., Kamiyama N., Takada H., Yamashita K., Matsuda A., J. Org. Chem., 61, 915-923 (1996).
10. Ono S., Shuto S., Matsuda A., Tetrahedron Lett., 37, 221-224 (1996).
11. Shuto S., Ono S., Hase Y., Kamiyama N., Matsuda A., Tetrahedron Lett., 37, 641-644 (1996).
12. Briley M., Drugs Future, 11, 21-23 (1986).
13. Moret C., Charveron M., Finberg J. P. M., Cozinier J., Briley M., Neuropharmacology, 24, 1211-1219 (1985).
14. Bonnaud B., Cousse H., Mouzin G., Briley M., Stenger A., Fauran F., Couzinier J.-P., J. Med. Chem., 30, 318-325 (1987).
15. Ansseau M., Papart P., Troisfontaines B., Bartholome F., Bataille M., Charles G., Schittecatte M., Darimont P., Devoitille J. M., Psychopharmacology, 114, 131-137 (1994).
16. Artigas F., CNS Drugs, 4, 79-89 (1995).
17. Shuto S., Ono S., Hase Y., Ueno Y., Noguchi T., Yoshii K., Matsuda A., J. Med. Chem., 39, 4844-4852 (1996).
18. Shuto S., Ono S., Imoto H., Yoshii K., Matsuda A., J. Med. Chem., 41, 3507-3514 (1998).
19. Noguchi T., Ishii K., Imoto H., Otubo Y., Shuto S., Ono S., Matsuda A., Yoshii K., Synapse, 31, 87-96 (1999).
20. Kazuta Y., Shuto S., Matsuda A., Tetrahedron Lett., 41, 5373-5377 (2000).
21. Shuto S., Yoshii K., Matsuda A., Jpn. J. Pharmacol., 85, 207-213 (2001).
22. Kazuta Y., Shuto S., Abe H., Matsuda A., J. Chem. Soc., Perkin Trans. 1, 2001, 599-604 (2001).
23. Uchino S., Watanabe W., Nakamura T., Shuto S., Kazuta Y., Matsuda A., Nakazima-Iijima S., Kohsaka S., Kudo Y., Mishina M., FEBS Lett., 69, 2007-2015 (2001).
24. Kazuta Y., Tsujita R., Uchino S., Kamiyama N., Mochizuki D., Yamashita K., Ohmori Y., Yamashita A., Yamamoto T., Kohsaka, S., Matsuda A., Shuto S., J. Chem. Soc., Perkin Trans. 1, 2002, 1199-1212 (2002).
25. Kazuta Y., Tsujita Y., Ogawa K., Hokonohara T., Yamashita K., Morino K., Matsuda A., Shuto S., Bioorg. Med. Chem., 10, 1777-1791 (2002).
26. Dingledine R., Borges K., Bowie D., Traynelis S., Pharmacol. Rev., 51, 7-61 (1999).
27. Brauner-Osbornel H., Egebjerg J., Nielsen E. O., Madsen U, Krogsgaad-Larsen P., J. Med. Chem., 43, 2609-2645 (2000).
28. Collingridge G. L., Watkins J. C. (ed.), "The NMDA Receptor," IRL Press at Oxford Univ. Press, Oxford, U.K., 1994.
29. Willetts J., Balster R. L., Leander J. D., Trends Pharmacol. Sci., 11, 423-428 (1990).
30. Tricklebank M. D., Singh L., Oles R. J., Preston C., Iversoen S. D., Eur. J. Pharmacol., 167, 127-135 (1989).
31. Rogawski M. A., Trends Pharmacol. Sci., 14, 325-331 (1993).
32. Olney J. W., Labruyere J., Price M. T., Science, 244, 1360-1362 (1989).
33. Meldrum B. S., Croucher M. J., Czuczwar S. J., Collins J. F., Curry K., Joseph M., Stone T. W., Neuroscience, 9, 925-930 (1983).
34. Hogan M. J., Gjedde A., Hakem A. M., J. Neurochem., 58, 186-191 (1992).
35. Shuto S., Takada H., Mochizuki D., Tsujita R., Hase Y., Ono S., Shibuya N., Matsuda A., J. Med. Chem., 38, 2964-2968 (1995).
36. States D. J., Haberkorn R. A., Ruben D. J., J. Mag. Reson., 48, 286-292 (1982).
37. Clore G. M., Nigles M., Sukumaran D. K., Brunger A. T., Karplus M., Gronenborn A. M., EMBO J., 5, 2729-2735 (1986).